Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.

Auteurs : Lambertini M, Fielding S, Loibl S, Janni W, Clark E, Franzoi MA, Fumagalli D, Caballero C, Arecco L, Salomoni S, Ponde NF, Poggio F, Kim HJ, Villarreal-Garza C, Pagani O, Paluch-Shimon S, Ballestrero A, Del Mastro L, Piccart M, Bines J, Partridge AH, de Azambuja E
Jaar : 2022
Journal : J Natl Cancer Inst
Volume : 114
Pagina's : 1117-1126

The first ones now, will later be last": understanding the importance of historical context when reading ESMO-MCBS scores."

Auteurs : Cherny NI, Dafni U, Pentheroudakis G, Piccart-Gebhart M, Zygoura P, Gyawali B, de Vries EGE
Jaar : 2022
Journal : ESMO Open
Volume : 7
Pagina's : 100413

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Auteurs : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Jaar : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pagina's : 38

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY

Auteurs : Gelber Rd, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhart M
Jaar : 2022
Journal : Eur J Cancer
Volume : 166
Pagina's : 219-228

Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations.

Auteurs : Conforti F, Pala L, Bagnardi V, De Pas T, Colleoni M, Buyse M, Hortobagyi G, Gianni L, Winer E, Loibl S, Cortes J, Piccart-Gebhart M, Wolff AC, Viale G, Gelber Rd
Jaar : 2022
Journal : JAMA Oncol
Volume : 8
Pagina's : 1668-1675

Systemic therapy for early-stage breast cancer: learning from the past to build the future.

Auteurs : Agostinetto E, Gligorov J, Piccart-Gebhart M
Jaar : 2022
Journal : Nat Rev Clin Oncol
Volume : 19
Pagina's : 763-774

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit.

Auteurs : Oosting SF, Barriuso J, Bottomley A, Galotti M, Gyawali B, Kiesewetter B, Latino NJ, Martinelli F, Pe M, Pentheroudakis G, Roitberg F, Vachon H, de Vries EGE, Piccart-Gebhart M, Cherny NI
Jaar : 2022
Journal : Ann Oncol

Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.

Auteurs : Martel S, Lambertini M, Agbor-Tarh D, Ponde NF, Gombos A, Paterson V, Hilbers F, Korde L, Manukyants A, Dueck A, Maurer C, Piccart-Gebhart M, Moreno-Aspitia A, Desmedt C, Di Cosimo S, de Azambuja E
Jaar : 2021
Journal : J Natl Compr Canc Netw
Volume : 19
Pagina's : 181-189

Impact of HIV infection on baseline characteristics and survival of women with breast cancer.

Auteurs : Brandão M, Bruzzone M, Franzoi MA, de Angelis C, Eiger D, Caparica R, Piccart-Gebhart M, Buisseret L, Ceppi M, Dauby N, Carrilho C, Lunet N, de Azambuja E, Lambertini M
Jaar : 2021
Journal : AIDS
Volume : 35
Pagina's : 605-618

Survival Impact and Cost-Effectiveness of a Multidisciplinary Tumor Board for Breast Cancer in Mozambique, Sub-Saharan Africa.

Auteurs : Brandão M, Guisseve A, Bata G, Firmino-Machado J, Alberto M, Ferro J, Garcia C, Zaqueu C, Jamisse A, Lorenzoni C, Piccart-Gebhart M, Leitão D, Come J, Soares O, Gudo-Morais A, Schmitt F, Tulsidás S, Carrilho C, Lunet N
Jaar : 2021
Journal : Oncologist
Volume : 26
Pagina's : e996-e1008

Immunotherapy for early breast cancer: too soon, too superficial, or just right?

Auteurs : Franzoi MA, Romano E, Piccart-Gebhart M
Jaar : 2021
Journal : Ann Oncol
Volume : 32
Pagina's : 323-336

STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial.

Auteurs : Sonnenblick A, Agbor-Tarh D, de Azambuja E, Hultsch S, Izquierdo M, Liu M, Pruneri G, Harbeck N, Piccart-Gebhart M, Moreno-Aspita A, Granit RZ, Rouas G, Fahoum I, Sotiriou C
Jaar : 2021
Journal : Int J Cancer
Volume : 148
Pagina's : 1529-1535

Integrated molecular and immune phenotype of HER2-positive breast cancer and response to neoadjuvant therapy: a NeoALTTO exploratory analysis.

Auteurs : Pizzamiglio S, Ciniselli CM, Triulzi T, Gargiuli C, De Cecco L, de Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Izquierdo M, Nuciforo P, Huober J, Cappelletti V, Cinieri S, Piccart-Gebhart M, Daidone MG, Pruneri G, Colombo MP, Tagliabue E, Verderio P, Di Cosimo S
Jaar : 2021
Journal : Clin Cancer Res

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Auteurs : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Jaar : 2021
Journal : NPJ Breast Cancer
Volume : 7
Pagina's : 125

A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.

Auteurs : Bardia A, Hurvitz SA, Rugo HS, Brufsky A, Cortes J, Loibl S, Piccart-Gebhart M, Cowden J, Spears P, Carey LA
Jaar : 2021
Journal : Future Oncol

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.

Auteurs : De Caluwe A, Buisseret L, Poortmans P, Van Gestel D, Salgado R, Sotiriou C, Larsimont D, Paesmans M, Craciun L, Drisis S, Vandekerckhove C, Reyal F, Veys I, Eiger D, Piccart-Gebhart M, Romano E, Ignatiadis M
Jaar : 2021
Journal : BMC Cancer
Volume : 21
Pagina's : 899

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.

Auteurs : Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HC, Saunders C, Cardoso F, Susnjar S, Bjelic-Radisic V, Smith KL, Piccart-Gebhart M, Korde LA, Goldhirsch A, Gelber Rd, Pagani O
Jaar : 2021
Journal : Breast
Volume : 59
Pagina's : 327-338

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.

Auteurs : Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart-Gebhart M, Loi S, Rothé F, Sotiriou C
Jaar : 2021
Journal : Clin Cancer Res
Volume : 27
Pagina's : 5607-5618

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.

Auteurs : Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart-Gebhart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI
Jaar : 2021
Journal : ESMO Open
Volume : 6
Pagina's : 100117

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

Auteurs : Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, OShaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS
Jaar : 2021
Journal : N Engl J Med
Volume : 384
Pagina's : 1529-1541